Celltrion has secured marketing authorisation from the European Commission (EC) for Avtozma (CT-P47), a biosimilar to Chugai ...

Purpose: The pharmacology, pharmacokinetics, clinical efficacy, safety, and role of tocilizumab in rheumatoid arthritis (RA) are reviewed. Summary: Tocilizumab is a novel monoclonal antibody that ...

Tocilizumab-anoh is approved for multiple conditions, including rheumatoid arthritis and COVID-19, in intravenous and subcutaneous formulations. Phase 3 study confirmed biosimilarity between ...

The Food and Drug Administration (FDA) has approved Avtozma ® (tocilizumab-anoh), a biosimilar to Actemra ® (tocilizumab), in both intravenous (IV) and subcutaneous (SC) formulations.

Over one third of patients with giant cell arteritis exhibit vascular inflammation even after receiving treatment with tocilizumab and glucocorticoids for at least 6 months, which suggests the ...

Avtozma, which is Celltrion’s twelfth biosimilar to be approved by the EC, is a recombinant humanised monoclonal antibody ...

The US Food and Drug Administration (FDA) has granted approval for Celltrion's Avtozma (tocilizumab-anoh) in both intravenous and subcutaneous formulations as an Actemra biosimilar for treating ...

Celltrion today announced that the European Commission (EC) has granted marketing authorization for Avtozma® (CT-P47), a ...

The FDA has approved a third biosimilar for tocilizumab, called Avtozma, the second such biosimilar to be available in both intravenous and subcutaneous formulations, according to a press release.

The biosimilar of IL-6 inhibitor tocilizumab, called Tyenne (formerly MSB11456), has been approved for the same indications as Roche’s brand, including rheumatoid arthritis, systemic juvenile ...

Reason for decision Not eligible for Health Technology Evaluation guidance Further information Decision makers have concluded that this technology will not progress as a potential technology appraisal ...

Findings showed tocilizumab-anoh had comparable efficacy, pharmacokinetics, safety, and immunogenicity with Actemra. The Food and Drug Administration (FDA) has approved Avtozma ® (tocilizumab ...